These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18376501)

  • 1. [Complex choices in respiratory tract infections: the search for simple solutions].
    Klugman K; Lode H
    Med Mal Infect; 2007 Nov; 37 Spec No 1():1. PubMed ID: 18376501
    [No Abstract]   [Full Text] [Related]  

  • 2. [Value of quantitative bacteriological examination of sputum in the evaluation of the effectiveness of chemotherapy of bacterial respiratory tract infections. I. Bacteriological studies].
    Przybyłkiewicz Z; Nikodemowicz E; Kasprowicz A; Owsiński J
    Pneumonol Pol; 1980 Aug; 48(8):535-43. PubMed ID: 6775309
    [No Abstract]   [Full Text] [Related]  

  • 3. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Hutchinson J
    N Engl J Med; 2002 Jul; 347(1):65-7; author reply 65-7. PubMed ID: 12102064
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antibacterial therapy of pneumococcal infections caused by drug resistant microorganisms].
    Sidorenko SV
    Antibiot Khimioter; 2002; 47(7):31-7. PubMed ID: 12516194
    [No Abstract]   [Full Text] [Related]  

  • 5. [Resistance of infectious agents involved in low respiratory tract infections in France].
    Varon E; Houssaye S
    Med Mal Infect; 2006; 36(11-12):555-69. PubMed ID: 16962730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The microbiologist's point of view].
    Gutmann L
    Presse Med; 2002 Nov; 31(37 Pt 2):S4-5. PubMed ID: 12489324
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel agents for the treatment of outpatient respiratory tract infections. Introduction.
    Pell DM
    Postgrad Med; 2002 Sep; 112(3 Suppl):5-6. PubMed ID: 19667592
    [No Abstract]   [Full Text] [Related]  

  • 8. [Empyema: bacterial epidemiology and antibiotic resistance].
    Vu-Thien H
    Arch Pediatr; 2008 Oct; 15 Suppl 2():S81-3. PubMed ID: 19000860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Associated With 30-Day Mortality Rate in Respiratory Infections Caused by Streptococcus pneumoniae.
    Cheng MP; Bogoch II; Green K; Plevneshi A; Rudnick W; Shigayeva A; McGeer A; Lee TC;
    Clin Infect Dis; 2018 Apr; 66(8):1282-1285. PubMed ID: 29140429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Continued or discontinued administration of antimicrobial agents in patients of the CARA group].
    Sluiter HJ
    Ned Tijdschr Geneeskd; 1976 Jul; 120(31):1337-9. PubMed ID: 7756
    [No Abstract]   [Full Text] [Related]  

  • 11. Ciprofloxacin vs. the pneumococcus.
    Karcic AA; Khan FA
    Chest; 2000 Oct; 118(4):1226-7. PubMed ID: 11035706
    [No Abstract]   [Full Text] [Related]  

  • 12. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections.
    Appelbaum PC
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial-resistant Streptococcus pneumoniae: trends and management.
    Jacobs MR
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):619-35. PubMed ID: 18847402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Compliance in antibiotic therapy of respiratory tract infections].
    Karpov OI
    Antibiot Khimioter; 1999; 44(8):37-45. PubMed ID: 10494389
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibiotic susceptibility of pathogens isolated from patients with community-acquired respiratory tract infections in Pakistan--the active study.
    Zafar A; Hussain Z; Lomama E; Sibille S; Irfan S; Khan E
    J Ayub Med Coll Abbottabad; 2008; 20(1):7-9. PubMed ID: 19024175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The clinician's point of view: decision aids].
    Schlemmer B
    Presse Med; 2002 Nov; 31(37 Pt 2):S3-4. PubMed ID: 12489323
    [No Abstract]   [Full Text] [Related]  

  • 17. Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae?
    Fenoll A; Aguilar L; Granizo JJ; Giménez MJ; Aragoneses-Fenoll L; Mendez C; Tarragó D
    J Antimicrob Chemother; 2008 Dec; 62(6):1430-3. PubMed ID: 18819966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolones in chronic obstructive pulmonary disease.
    Colville A; Knowles M; Large D; George J; Mustchin P
    BMJ; 1994 May; 308(6941):1437. PubMed ID: 8019265
    [No Abstract]   [Full Text] [Related]  

  • 19. Derriere to the future: is it time to rethink how we use antimicrobial agents?
    Tillotson GS
    Clin Infect Dis; 2001 Apr; 32(8):1189-90. PubMed ID: 11283808
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
    Rapp RP
    Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.